Text size: click to decrease font sizeclick to increase font size (click to alter)
London sarcoma service

Royal National Orthopaedic Hospital NHS Trust

University College London Hospitals NHS Foundation Trust

LSESN logo image

our approach & expertise


research & clinical trials


currently open trials

ANNOUNCE 2: A phase Ib (open label)/Phase II (only) randomized, double-blinded study evaluating the efficacy of Gemcitabine and Docetaxel with or without a human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma (Academic)

Bone Sarcoma CTC study: Optimisation of circulating tumour cell detection in bone sarcomas

CaboGIST EORTC 1317:  Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumour (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and suntinib

ESPRIT: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

EE 2012 - an international randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours

EZH202 - A phase II, multicentre study of the EZH202 Inhibitor Tazemetostat in adult subjects with INI1-Negative tumours or relapsed refractory Synovial and Epitheliod type.

HGUS EORTC 62113 : A randomised double-blind phase II study evaluating the role of maintenance cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) or response to doxorubicin +/-ifosfamide or in metastatic first line treatment

HOPE: Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults withOsteosarcoma

IMRIS: A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma

Kindred Study: The International Sarcoma Kindred Study: a global multi-site prospective cancer genetics study

RAPPER: Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy

rEECUr: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

SSG XXII: A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor imastinib mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence


Sometimes there may be other trials open - it is always worth asking your doctor.